Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors - Huang, Chun-Ta; Lin, Chih-An; Su, Te-Jen; Yang, Ching-Yao; Tsai, Tzu-Hsiu; Hsu, Chia-Lin; Liao, Wei-Yu; Chen, Kuan-Yu; Ho, Chao-Chi; Yu, Chong-Jen (BMC cancer, 2023)
Keywords: Adenocarcinoma; Afatinib - therapeutic use; Biopsy; Cancer therapies; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Development and progression; Droplet digital polymerase chain reaction; Drug Resistance, Neoplasm - genetics; Drug therapy; EGFR mutation; Epidermal growth factor receptors; ErbB Receptors - genetics; Erlotinib Hydrochloride - therapeutic use; Gefitinib; Gefitinib - therapeutic use; Gene mutations; Genotyping; Health aspects; Humans; Inhibitor drugs; Laboratories; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Medical research; Mutants; Mutation; Non-small cell lung carcinoma; Osimertinib; Plasma; Polymerase chain reaction; Prospective Studies; Protein Kinase Inhibitors - therapeutic use; Targeted cancer therapy; Testing; Tyrosine kinase inhibitor; Tyrosine Kinase Inhibitors; Taiwan; United States--US; EGFR mutation; Osimertinib; Tyrosine kinase inhibitor; Droplet digital polymerase chain reaction; Lung cancer